 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Blockbuster Results for Cancer Drug - Mar 4th News Release and more.... IGT Pharma Inc - News Release Anti-cancer drug test results IGT Pharma Inc IGT Shares issued 6581332 1997-03-03 close $0.68 Tuesday Mar 4 1997 News Release Mr Bruce Schmidt reports Pre-clinical studies conducted at the BC Cancer Agency using Anhydrovinblastine (AVLB), the company's patented anti cancer drug, have shown excellent preliminary results in reducing tumors relating to human lung cancer. In a comparative study with Navelbine, Glaxo's successful anti-cancer drug, it was found that after 23 days, tumors treated with AVLB were seven times smaller than those treated with Navelbine. In comparison to a selection of other drugs used to treat cancer, AVLB has proved itself to be highly effective on a range of tumor types while showing generally reduced toxic side effects. AVLB, In its final stages of pre-clinical assessment, is scheduled for phase I clinical trials later this year. IGT is currently in the process of confirming all relevant data pertaining to AVLB in preparation for the clinical trials application. (c) Copyright 1997 Canjex Publishing Ltd. canada-stockwatch.com _______________________________________________________________________ IGT International Growth Technologies - News Release IRAP grant for Etoposide development IGT International Growth Technologies IGT Shares issued 6261332 1997-02-25 close $0.51 Tuesday Feb 25 1997 News Release Mr Bruce Schmidt reports The National Research Council - IRAP program has extended the company's existing grant for development work on the synthesis of the generic anti-cancer drug, Etoposide. Etoposide, one of the world's most successful cancer drugs for the treatment of solid tumors, has an annual market of approximately $400 million. Etoposide is now only extracted from plants and therefore has an expensive cost base. The company's technical focus will be to develop the first synthetic production alternative using only common starting materials. Progress to date has been extremely encouraging and will allow the company to file patent applications within the next two to three months. Following patent and production scale-up activities, the company will approach its existing contacts in the pharmaceutical industry to arrange for joint venture or licencing of distribution rights. ______________________________________ | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |